Multishield DC Intramammary Suspension for Cows

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Neomycin Sulphate, Penethamate Hydriodide, micronised, Procaine Benzylpenicillin

Available from:

Bimeda Animal Health Limited

ATC code:

QJ51RC22

INN (International Name):

Neomycin Sulphate, Penethamate Hydriodide, micronised, Procaine Benzylpenicillin

Pharmaceutical form:

Intramammary suspension

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Cattle

Therapeutic area:

Antimicrobial

Authorization status:

Authorized

Authorization date:

2013-05-02

Summary of Product characteristics

Revised: October 2018
AN: 00818/2018
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Multishield DC Intramammary Suspension for Cows
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 4.5g intramammary syringe contains
Active Substances:
Neomycin
70 000 IU
(corresponding to Neomycin Sulphate
100 mg)
Penethamate
77.2 mg
(corresponding to Penethamate Hydriodide
100 mg)
Benzylpenicillin
227.2 mg
(corresponding to Procaine Benzylpenicillin
400 mg)
Excipients:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Intramammary suspension.
A smooth, off white, oily suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cows (at dry off)
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In cows at drying off:
Treatment of subclinical mastitis caused by bovine mastitis
microorganisms
susceptible to the combination of active substances, penicillin and
neomycin, and
as part of strategy for the prevention of new infections occurring
during the dry
period.
4.3
CONTRAINDICATIONS
Do not use in lactating cows.
Do not use in cases of hypersensitivity to β-lactam antibiotics,
cephalosporin
antibiotics, neomycin or other aminoglycoside antibiotics or to any of
the
excipients.
Do not use in cows with clinical mastitis.
4.4
SPECIAL WARNINGS
None.
Revised: October 2018
AN: 00818/2018
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use of the product should be based on susceptibility testing of the
bacteria
isolated from the animal. If this is not possible, therapy should be
based on local
(regional, farm level) epidemiological information about
susceptibility of the target
bacteria.
Official, national and regional antimicrobial policies should be taken
into account
when the product is used.
The therapeutic efficacy of the product is only established against
pathogens that
are susceptible to the active substances.
Serious acute mastitis [potentially lethal] due to pathogens like
_Pseudomonas _
_aeruginosa_, can occur after drying off de